Genentech - CA41705

Brief description of study

The purpose of this study is to compare the effects, good or bad, of the study drug called obinutuzumab (also known as Gazyva or Gazyvaro) versus placebo on patients with lupus nephritis. Obinutuzumab is currently Food and DrugAdministration (FDA) approved for use for the treatment of blood cancers called chronic lymphocytic leukemia and follicular lymphoma and is being investigated for the treatment of other blood cancers. However, obinutuzumab is an experimental drug for lupus nephritis, which means the FDA has not approved obinutuzumab for the treatment of lupus nephritis. Roche is conducting this study to see if using obinutuzumab to reduce B cells will improve the signs and symptoms of lupus nephritis.

Clinical Study Identifier: s19-01883 Identifier: NCT04221477
Principal Investigator: Amit Saxena.
Other Investigator: Janine M. Sullivan.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.